Jason M Warram

List of Publications by Year
in descending order

67 papers	3,076 citations	172457 29 h-index	161849 54 g-index
69 all docs	69 docs citations	69 times ranked	3925 citing authors

#	Article	IF	Citations
1	Beyond the margins: real-time detection of cancer using targeted fluorophores. Nature Reviews Clinical Oncology, 2017, 14, 347-364.	27.6	366
2	Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer. Clinical Cancer Research, 2015, 21, 3658-3666.	7.0	355
3	Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence. Cancer Research, 2018, 78, 5144-5154.	0.9	143
4	Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report. Journal of Nuclear Medicine, 2016, 57, 144-150.	5.0	125
5	Oncologic Procedures Amenable to Fluorescence-guided Surgery. Annals of Surgery, 2017, 266, 36-47.	4.2	119
6	Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers. Theranostics, 2018, 8, 2488-2495.	10.0	113
7	The Status of Contemporary Image-Guided Modalities in Oncologic Surgery. Annals of Surgery, 2015, 261, 46-55.	4.2	112
8	Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer. Clinical Cancer Research, 2017, 23, 4744-4752.	7.0	105
9	Antibody-based imaging strategies for cancer. Cancer and Metastasis Reviews, 2014, 33, 809-822.	5.9	103
10	A Triple‑Targeted Ultrasound Contrast Agent Provides Improved Localization to Tumor Vasculature. Journal of Ultrasound in Medicine, 2011, 30, 921-931.	1.7	82
11	Microbubble-mediated ultrasonic techniques for improved chemotherapeutic delivery in cancer. Journal of Drug Targeting, 2012, 20, 43-54.	4.4	79
12	In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas. Scientific Reports, 2015, 5, 10169.	3.3	76
13	Regulatory Aspects of Optical Methods and Exogenous Targets for Cancer Detection. Cancer Research, 2017, 77, 2197-2206.	0.9	74
14	Breast Tumor Xenografts: Diffusion-weighted MR Imaging to Assess Early Therapy with Novel Apoptosis-Inducing Anti-DR5 Antibody. Radiology, 2008, 248, 844-851.	7.3	61
15	Surgical margins in oral cavity squamous cell carcinoma: Current practices and future directions. Laryngoscope, 2020, 130, 128-138.	2.0	54
16	Fluorescence Imaging of Nerves During Surgery. Annals of Surgery, 2019, 270, 69-76.	4.2	52
17	Recommendations for reporting on emerging optical imaging agents to promote clinical approval. Theranostics, 2018, 8, 5336-5347.	10.0	51
18	Determination of Breast Cancer Response to Bevacizumab Therapy Using Contrast-Enhanced Ultrasound and Artificial Neural Networks. Journal of Ultrasound in Medicine, 2010, 29, 577-585.	1.7	50

#	Article	IF	Citations
19	SPARC-Independent Delivery of <i>Nab</i>-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Molecular Cancer Therapeutics, 2016, 15, 680-688.	4.1	49
20	Fluorescence Imaging for Cancer Screening and Surveillance. Molecular Imaging and Biology, 2017, 19, 645-655.	2.6	47
21	Early Therapy Evaluation of Combined Antiâ€"Death Receptor 5 Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts by Diffusion-Weighted Magnetic Resonance Imaging. Cancer Research, 2008, 68, 8369-8376.	0.9	45
22	Laparoscopic Fluorescent Visualization of the Ureter With Intravenous IRDye800CW. Journal of Minimally Invasive Gynecology, 2015, 22, 799-806.	0.6	44
23	Endotoxin-Induced Proteolytic Reduction in Hepatic Growth Hormone (GH) Receptor: A Novel Mechanism for GH Insensitivity. Molecular Endocrinology, 2008, 22, 1427-1437.	3.7	40
24	Volumetric Contrastâ€"Enhanced Ultrasound Imaging of Renal Perfusion. Journal of Ultrasound in Medicine, 2014, 33, 1427-1437.	1.7	39
25	Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CW. British Journal of Neurosurgery, 2015, 29, 850-858.	0.8	38
26	Specimen mapping in head and neck cancer using fluorescence imaging. Laryngoscope Investigative Otolaryngology, 2017, 2, 447-452.	1.5	37
27	Characterizing the Utility and Limitations of Repurposing an Open-Field Optical Imaging Device for Fluorescence-Guided Surgery in Head and Neck Cancer Patients. Journal of Nuclear Medicine, 2017, 58, 246-251.	5.0	35
28	Photoimmunotherapy of residual disease after incomplete surgical resection in head and neck cancer models. Cancer Medicine, 2016, 5, 1526-1534.	2.8	32
29	Fluorescence imaging to localize head and neck squamous cell carcinoma for enhanced pathological assessment. Journal of Pathology: Clinical Research, 2016, 2, 104-112.	3.0	32
30	Effects of an Unlabeled Loading Dose on Tumor-Specific Uptake of a Fluorescently Labeled Antibody for Optical Surgical Navigation. Molecular Imaging and Biology, 2017, 19, 610-616.	2.6	30
31	Ultrasoundâ€"Triggered Delivery of Anticancer Therapeutics from MRIâ€"Visible Multilayer Microcapsules. Advanced Therapeutics, 2018, 1, 1800051.	3.2	30
32	Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. Theranostics, 2019, 9, 5085-5104.	10.0	29
33	Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1412-1426.	6.4	29
34	Alpha-CaMKII Plays a Critical Role in Determining the Aggressive Behavior of Human Osteosarcoma. Molecular Cancer Research, 2013, 11, 349-359.	3.4	28
35	A Standardized Light-Emitting Diode Device for Photoimmunotherapy. Journal of Nuclear Medicine, 2014, 55, 1893-1898.	5.0	27
36	Ultrasound-Stimulated Drug Delivery for Treatment of Residual Disease after Incomplete Resection of Head and Neck Cancer. Ultrasound in Medicine and Biology, 2014, 40, 755-764.	1.5	25

#	Article	IF	Citations
37	A ratiometric threshold for determining presence of cancer during fluorescence-guided surgery. Journal of Surgical Oncology, 2015, 112, 2-8.	1.7	25
38	Molecular Targeting of Ultrasonographic Contrast Agent for Detection of Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology, 2012, 138, 662.	1.2	24
39	Panitumumab-IRDye800CW for Fluorescence-Guided Surgical Resection of Colorectal Cancer. Journal of Surgical Research, 2019, 239, 44-51.	1.6	23
40	Molecular Ultrasound Imaging of Tissue Inflammation Using an Animal Model of Acute Kidney Injury. Molecular Imaging and Biology, 2015, 17, 786-792.	2.6	21
41	Optical fluorescent imaging to monitor temporal effects of microbubble-mediated ultrasound therapy. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2013, 60, 281-289.	3.0	17
42	Fibroblast Growth Factor Receptor Mediates Fibroblast-Dependent Growth in EMMPRIN-Depleted Head and Neck Cancer Tumor Cells. Molecular Cancer Research, 2011, 9, 1008-1017.	3.4	16
43	Model System Using Controlled Receptor Expression for Evaluating Targeted Ultrasound Contrast Agents. Ultrasound in Medicine and Biology, 2011, 37, 1306-1313.	1.5	15
44	Biodistribution of P-selectin targeted microbubbles. Journal of Drug Targeting, 2014, 22, 387-394.	4.4	15
45	Characterizing the detection threshold for optical imaging in surgical oncology. Journal of Surgical Oncology, 2017, 116, 898-906.	1.7	14
46	A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma. Oncogene, 2020, 39, 6961-6974.	5.9	12
47	Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme. Molecular Cancer Therapeutics, 2020, 19, 1922-1929.	4.1	12
48	Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer. PLoS ONE, 2020, 15, e0229077.	2.5	12
49	An Animal Model Allowing Controlled Receptor Expression for Molecular Ultrasound Imaging. Ultrasound in Medicine and Biology, 2013, 39, 172-180.	1.5	11
50	Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies. Cancer Biology and Therapy, 2015, 16, 790-798.	3.4	11
51	A Genetic Strategy for Combined Screening and Localized Imaging of Breast Cancer. Molecular Imaging and Biology, 2011, 13, 452-461.	2.6	10
52	Enhancement of Adenovirus Delivery after Ultrasound-Stimulated Therapy in a Cancer Model. Ultrasound in Medicine and Biology, 2013, 39, 2374-2381.	1.5	10
53	Laser-Assisted Indocyanine Green Dye Angiography for Postoperative Fistulas After Salvage Laryngectomy. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 775.	2.2	10
54	Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies. Laryngoscope, 2016, 126, E387-E395.	2.0	8

#	Article	IF	Citations
55	On the horizon: Optical imaging for cutaneous squamous cell carcinoma. Head and Neck, 2016, 38, E2204-13.	2.0	8
56	Evaluation of fluorescence‐guided surgery agents in a murine model of soft tissue fibrosarcoma. Journal of Surgical Oncology, 2018, 117, 1179-1187.	1.7	8
57	Evaluation of optical imaging agents in a fluorescence-guided surgical model of head and neck cancer. Surgical Oncology, 2018, 27, 225-230.	1.6	8
58	Fluorescently Labeled Cetuximab-IRDye800 for Guided Surgical Excision of Ameloblastoma: A Proof of Principle Study. Journal of Oral and Maxillofacial Surgery, 2020, 78, 1736-1747.	1.2	8
59	Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis. Cancer Biology and Therapy, 2009, 8, 1109-1116.	3.4	5
60	Genetic strategy to decrease complement activation with adenoviral therapies. PLoS ONE, 2019, 14, e0215226.	2.5	4
61	Adjuvant anti-angiogenic therapy enhances chemotherapeutic uptake in a murine model of head and neck cancer. Journal of Drug Targeting, 2019, 27, 193-200.	4.4	3
62	Predicting Schwannoma Growth in a Tumor Model Using Targeted Imaging. Otology and Neurotology, 2021, 42, e615-e623.	1.3	2
63	Quantitative elasticity measurements reveal intratumoral changes in response to antiangiogenic therapy - preliminary results. , 2009, , .		1
64	Validation of controlled receptor expression using adenoviral techniques and targeted ultrasound imaging. , 2010, , .		0
65	Molecular ultrasound imaging using a novel tumor-bearing animal model with variable target receptor expression. , 2012, , .		0
66	Defining the Detection Threshold for Optical Imaging in Surgical Resection. Journal of the American College of Surgeons, 2014, 219, S128.	0.5	0
67	Hyperintensity of integrin‐targeted fluorescence agent IntegriSense750 accurately predicts flap necrosis compared to Indocyanine green. Head and Neck, 2021, , .	2.0	0